Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Revolving Door Of Executive Changes At Perrigo As Firm Revises Its Expectations Up

Firm Has Experienced Notable Disruption Due To Ukraine Conflict

Executive Summary

Perrigo is set to welcome a new chief financial officer and corporate security head as it rounds up a fairly successful first quarter.

You may also be interested in...



Perrigo Boosts 2022 Guidance Shifting From Changing Organization To Delivering Results

“We said we would start growing this company ... and this is the year to do it,” says CERO Murray Kessler. With nearly 11% net sales growth for its Americas business leading nearly 10% overall Q1 growth, Perrigo raises full-year guidance for net sales growth to 8% to 9%, up earlier 7% to 8%.

Perrigo Trades Rx For HRA With €1.8bn Acquisition

Perrigo has announced a deal to acquire consumer healthcare company HRA Pharma for €1.8bn. The move comes after the firm shed the majority of its prescription pharmaceuticals interests in recent years and completes its transformation into a fully self-care focused company.

Inflation Impact Must Be Considered During Generics Pricing, Says Canadian Study

Canadian provinces must consider the impact of inflation on generic drugs during the next round of off-patent price setting, says a study from Aviseo and the Canadian Generic Pharmaceutical Association.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151876

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel